On the stock market since 2018, it operates in the world of health and science. It has 2,506 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 27% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades below its recent peak — about 9% off the top. A pullback, not a collapse.
Over the last 3 years, sales grew about 30% a year on average.
The company sells $982.0M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $416.3M against $982.0M in annual sales.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 49/100.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, GH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GH has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.